Sangamo Therapeutics Inc
NASDAQ: SGMO · HEALTHCARE · BIOTECHNOLOGY
Updated 2026-06-05
Sangamo Therapeutics Inc (SGMO) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-14.48M | $-16.07M | $-17.34M | $-6.14M | $-23.93M | $-25.89M | $-8.08M | $-19.48M | $-5.67M | $-33.72M | $-65.88M | $11.18M | $37.15M | $-144.40M | $169.88M | $-233.25M | $-223.63M | $-224.84M | $-67.14M | $-97.21M |
| Capital expenditures | $374000.00 | $1.37M | $739000.00 | $272000.00 | $695000.00 | $576000.00 | $723000.00 | $432000.00 | $621000.00 | $2.41M | $732000.00 | $3.75M | $43.06M | $20.68M | $14.71M | $23.28M | $20.17M | $21.16M | $267000.00 | $102000.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $2.02M | $2.44M | $5.75M | $8.47M | $7.82M | $8.08M | $5.34M | $6.15M | $9.20M | $11.73M | $15.06M | $9.09M | $14.68M | $19.33M | $25.71M | $32.96M | $31.65M | $27.36M | $12.38M | $9.08M |
| Free cash flow | $-14.85M | $-17.44M | $-18.08M | $-6.41M | $-24.63M | $-26.47M | $-8.80M | $-19.91M | $-6.30M | $-36.13M | $-66.61M | $7.43M | $-5.91M | $-165.08M | $155.16M | $-256.53M | $-243.80M | $-246.00M | $-67.41M | $-97.31M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | $5.98M | $4.91M | $-11.49M | $-4.16M | $63.45M | $-47.42M | $27.77M | $90.75M | $-62.17M | $51.35M | $47.81M | $-79.68M | — | — | — |
Frequently asked questions
What is Sangamo Therapeutics Inc's revenue?
Sangamo Therapeutics Inc's trailing twelve-month revenue is $34.56M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.
How profitable is SGMO?
In its most recent fiscal year, SGMO ran a gross margin of 80.78%, an operating margin of -273.07%, and a net margin of -310.81%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.
How much free cash flow does SGMO generate?
SGMO produced $-97.31M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.